News
Dr. Scott Gottlieb, former US FDA Commissioner, joins Illumina’s Board of Directors
Illumina, Inc. (NASDAQ: ILMN) announced today that Scott Gottlieb, M.D. has joined the company’s Board of Directors, effective February 4, 2020. Dr. Gottlieb is currently a special partner at the
Dr. Scott Gottlieb, former US FDA Commissioner, joins Illumina’s Board of Directors
Illumina, Inc. (NASDAQ: ILMN) announced today that Scott Gottlieb, M.D. has joined the company’s Board of Directors, effective February 4, 2020. Dr. Gottlieb is currently a special partner at the
Problem Zivilisationskrankheiten? Eher nicht für Aktionäre von Edwards Lifesciences...
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2019 Financial Results
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PST/4:30 p.m. EST on Thursday, February 20, 2020, following release of its fourth
Aimmune Licenses Exclusive Worldwide Rights to Xencor’s XmAb®7195 for the Development of Next-Generation Food Allergy Treatments
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, announced it has granted an
Aduro Biotech: +142% – Alltag im No Brainer Club
Für die Oktober-Empfehlung des No Brainer Clubs geht es weiter in die Höhe: Aduro Biotech (WKN: A14Q7F) bescherte NBC-Mitgliedern bis heute bereits einen Gewinn von +142%.
Nach dem Erreichen der
Premier Inc. to Acquire Acurity and Nexera Businesses from the Greater New York Hospital Association
Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, today announced that it has entered into a definitive agreement to acquire substantially all the assets and certain
Premier Inc. Reports Fiscal 2020 Second-Quarter Results
Premier Inc. (NASDAQ: PINC) today reported financial results for the fiscal 2020 second quarter ended Dec. 31, 2019.
All results presented in this press release reflect continuing operations
Lantheus Announces Topline Results for BENEFIT 1 LVEF Clinical Trial
Lantheus Holdings, Inc. (NASDAQ: LNTH) (“Lantheus” or the “Company”), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a leader in the development, manufacture and commercialization of
Clovis Oncology Announces Availability and Reimbursement for Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in France
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that Rubraca® (rucaparib) is now available and reimbursed in France. Rubraca® (rucaparib) is an option for monotherapy maintenance treatment for
Pfizer Receives Positive CHMP Opinion for Oncology Biosimilar, RUXIENCE™ (rituximab)
Pfizer Inc. (NYSE: PFE) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending marketing
Pfizer Receives Positive CHMP Opinion for Oncology Biosimilar, RUXIENCE™ (rituximab)
Pfizer Inc. (NYSE: PFE) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending marketing
Agilent Teams with Indian Institute of Technology Delhi to Enhance Biotherapeutics
Agilent Technologies Inc. (NYSE: A) today announced that it is joining forces with the Indian Institute of Technology Delhi (IIT Delhi) to promote biopharmaceutical research.
Agilent and IIT
Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2019
Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the fourth quarter and fiscal year 2019.
Fourth quarter 2019 results:
-
Revenue of $953 million, a 10% increase compared
Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2019
Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the fourth quarter and fiscal year 2019.
Fourth quarter 2019 results:
-
Revenue of $953 million, a 10% increase compared
Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2019
Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the fourth quarter and fiscal year 2019.
Fourth quarter 2019 results:
-
Revenue of $953 million, a 10% increase compared
Pulmatrix: Wann folgt die Explosion 2.0?
Mit einem Schlusskurs von 1,78 USD markierte die Aktie von Pulmatrix (WKN: A2PD3T) gestern ein neues Langzeithoch. Obwohl NBC-Mitglieder auch hier bereits auf teilweise über +100% Gewinn sitzen
Agilent Technologies to Webcast First Quarter Fiscal Year 2020 Financial Results Conference Call
Agilent Technologies, Inc. (NYSE: A) will release first-quarter fiscal year 2020 financial results after the stock market closes on Feb. 18. The company will also host a live webcast of its
Quidel to Hold Fourth Quarter and Full Year 2019 Financial Results Conference Call on February 12th, 2020
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, will report fourth quarter and full year 2019
Acceleron Pharma: Bluthochdruck!
Die Aktie von Acceleron Pharma (WKN: A1W5LE) gehört heute zu den ganz großen Gewinnern am US-Aktienmarkt und kann um sage und schreibe mehr als +50% zulegen.
Dabei handelt es sich bei Acceleron
LivaNova to Host Conference Call for Fourth Quarter and Full-Year 2019 Results
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its fourth quarter and full-year 2019 results on Wednesday, Feb. 26
CommonSpirit Health Chooses Premier Inc. to Clinically Integrate its Newly Merged Supply Chain
CommonSpirit Health will be partnering with Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, to achieve operational excellence as it undergoes the complex integration of its
PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2019 RESULTS
Pfizer Inc. (NYSE: PFE) reported financial results for fourth-quarter and full-year 2019 and provided 2020 financial guidance.
Results for the fourth quarter and the full year of 2019 and 2018(7)
PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2019 RESULTS
Pfizer Inc. (NYSE: PFE) reported financial results for fourth-quarter and full-year 2019 and provided 2020 financial guidance.
Results for the fourth quarter and the full year of 2019 and 2018(7)
Agilent Introduces New Cutting-Edge SureSelect DNA Kit
Agilent Technologies Inc. (NYSE: A) today introduced a new product designed to address key challenges that laboratories encounter when preparing DNA sequencing libraries for their research. The new